Fruquintinib as first-line or second-line treatment in unresectable or metastatic soft-tissue sarcoma: A prospective, single-arm phase II study

Xiaowei Zhang; Ting Zhao; Biqiang Zheng; Wangjun Yan; Yong Chen; Yu Xu; Chunmeng Wang; Junhua Zhang; Jian Wang; Lin Yu; Xin Liu; Zhiguo Luo

doi:10.1002/ctm2.70308

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (4) : e70308 DOI: 10.1002/ctm2.70308

LETTER TO THE JOURNAL

Fruquintinib as first-line or second-line treatment in unresectable or metastatic soft-tissue sarcoma: A prospective, single-arm phase II study

Xiaowei Zhang ¹^,²
, Ting Zhao ¹^,²
, Biqiang Zheng ²^,³
, Wangjun Yan ²^,³
, Yong Chen ²^,³
, Yu Xu ²^,³
, Chunmeng Wang ²^,³
, Junhua Zhang ²^,⁴
, Jian Wang ²^,⁵
, Lin Yu ²^,⁵
, Xin Liu ¹^,²
, Zhiguo Luo ¹^,²

Author information +

History +

PDF

Cite this article

Download citation ▾

Xiaowei Zhang, Ting Zhao, Biqiang Zheng, Wangjun Yan, Yong Chen, Yu Xu, Chunmeng Wang, Junhua Zhang, Jian Wang, Lin Yu, Xin Liu, Zhiguo Luo. Fruquintinib as first-line or second-line treatment in unresectable or metastatic soft-tissue sarcoma: A prospective, single-arm phase II study. Clinical and Translational Medicine, 2025, 15(4): e70308 DOI:10.1002/ctm2.70308

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine. CA Cancer J Clin.2020; 70: 200-229.

[2]	von Mehren M, Kane JM, Agulnik M, et al. Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw.2022; 20: 815-833.

[3]	Hardy NJ, Deshpande HA, Olino K, Costa PA. Survival trends of soft tissue sarcomas and gastrointestinal stromal tumors from 1995 to 2019: a SEER database analysis. J Clin Oncol.2024; 42: e23528-e23528.

[4]	Spalato-Ceruso M, Ghazzi NE, Italiano A. New strategies in soft tissue sarcoma treatment. J Hematol Oncol.2024; 17: 76.

[5]	van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet.2012; 379: 1879-1886.

[6]	Li T, Dong Y, Wei Y, et al. First-line anlotinib treatment for soft-tissue sarcoma in chemotherapy-ineligible patients: an open-label, single-arm, phase 2 clinical trial. Clin Cancer Res.2024; 30: 4310-4317.

[7]	Zhou C, Qian G, Wang Y, Li H, Shen Z, Zheng S. Safety and efficacy of fruquintinib-based therapy in patients with advanced or metastatic sarcoma. Cancer Med.2024; 13: e7438.

[8]	Dasari A, Lonardi S, Garcia-Carbonero R, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet.2023; 402: 41-53.

[9]	Yang C, Li B, Dong S, et al. Efficacy and safety of fruquintinib-based treatment in patients with refractory bone and soft tissue sarcoma after developing resistance to several TKIs: a multicenter retrospective study. Orthop Surg.2024; 16: 2380-2390.

[10]	Ding X, Liu Y, Zhang Y, et al. Efficacy and safety of fruquintinib as third- or further-line therapy for patients with advanced bone and soft tissue sarcoma: a multicenter retrospective study. Anticancer Drugs.2023; 34: 877-882.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.